Zacks: Brokerages Expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Will Announce Quarterly Sales of $522.51 Million

Equities research analysts predict that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will post $522.51 million in sales for the current quarter, according to Zacks. Eight analysts have provided estimates for Jazz Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $515.40 million and the highest estimate coming in at $527.00 million. Jazz Pharmaceuticals reported sales of $469.37 million in the same quarter last year, which indicates a positive year over year growth rate of 11.3%. The company is scheduled to issue its next quarterly earnings results on Tuesday, November 5th.

On average, analysts expect that Jazz Pharmaceuticals will report full-year sales of $2.11 billion for the current year, with estimates ranging from $2.09 billion to $2.15 billion. For the next financial year, analysts forecast that the business will report sales of $2.34 billion, with estimates ranging from $2.26 billion to $2.39 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.16 by $0.49. Jazz Pharmaceuticals had a return on equity of 27.72% and a net margin of 32.99%. The firm had revenue of $534.13 million for the quarter, compared to analyst estimates of $507.23 million. During the same quarter in the prior year, the firm posted $3.49 earnings per share. The company’s quarterly revenue was up 6.7% on a year-over-year basis.

Several equities analysts have weighed in on the company. Royal Bank of Canada set a $184.00 target price on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, July 3rd. Oppenheimer set a $176.00 target price on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, September 26th. Sanford C. Bernstein reissued a “market perform” rating and issued a $150.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, October 14th. Mizuho set a $148.00 target price on Jazz Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, July 3rd. Finally, HC Wainwright reissued a “hold” rating and issued a $147.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 8th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the stock. Jazz Pharmaceuticals has a consensus rating of “Hold” and an average target price of $167.20.

NASDAQ:JAZZ opened at $119.65 on Friday. Jazz Pharmaceuticals has a 1-year low of $113.52 and a 1-year high of $165.66. The business’s 50-day moving average price is $126.27 and its two-hundred day moving average price is $133.10. The company has a current ratio of 3.71, a quick ratio of 3.52 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $6.86 billion, a price-to-earnings ratio of 9.78, a PEG ratio of 1.49 and a beta of 1.11.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $130.00, for a total value of $65,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Catherine A. Sohn sold 726 shares of the stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $135.65, for a total value of $98,481.90. Following the completion of the sale, the director now owns 9,574 shares of the company’s stock, valued at $1,298,713.10. The disclosure for this sale can be found here. Insiders sold 5,597 shares of company stock valued at $764,057 over the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 2.2% during the second quarter. Charles Schwab Investment Management Inc. now owns 457,226 shares of the specialty pharmaceutical company’s stock worth $65,183,000 after buying an additional 9,797 shares in the last quarter. HBK Sorce Advisory LLC bought a new position in shares of Jazz Pharmaceuticals during the second quarter worth about $324,000. CENTRAL TRUST Co grew its holdings in shares of Jazz Pharmaceuticals by 256.4% during the second quarter. CENTRAL TRUST Co now owns 1,522 shares of the specialty pharmaceutical company’s stock worth $210,000 after buying an additional 1,095 shares in the last quarter. Chicago Equity Partners LLC grew its holdings in shares of Jazz Pharmaceuticals by 152.4% during the second quarter. Chicago Equity Partners LLC now owns 16,760 shares of the specialty pharmaceutical company’s stock worth $2,389,000 after buying an additional 10,120 shares in the last quarter. Finally, Zacks Investment Management bought a new position in shares of Jazz Pharmaceuticals during the second quarter worth about $1,626,000. Institutional investors and hedge funds own 87.54% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: How does new data get added to a blockchain?

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.